WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: FT: AstraZeneca and Bristol-Myers Squibb plan $400bn merger — Warptech Lab News

Storia in 18 fonti

FT: AstraZeneca and Bristol-Myers Squibb plan $400bn merger

AstraZeneca could merge with Bristol-Myers Squibb to form the world’s fourth-largest pharmaceutical company at combined $400bn market cap.

Raccontata da

www1.folha.uol.com.br

straitstimes.com

tgcom24.mediaset.it

ilsole24ore.com

handelsblatt.com

manager-magazin.de

morningstar.com+6 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

siliconrepublic.comStai leggendo2 h fa

FT: AstraZeneca and Bristol-Myers Squibb plan $400bn merger

AstraZeneca could merge with Bristol-Myers Squibb to form the world’s fourth-largest pharmaceutical company at combined $400bn market cap.

Timeline cronologica

domenica 2 agosto 2026·www1.folha.uol.com.br
AstraZeneca negocia fusão com Bristol Myers Squibb em acordo de US$ 400 bi
Acordo pode criar a quarta maior farmacêutica do mundo por capitalização de mercado
domenica 2 agosto 2026·cnbc.com
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.

newsbytesapp.com

1 g fa

AstraZeneca, BMS discuss $400B pharma mega-deal

AstraZeneca is reportedly exploring a $400 billion merger with U.S.-based Bristol Myers Squibb, potentially forming one of the largest pharmaceutical companies in history.

Leggi questa versione → originale

cityam.com1 g fa

Astrazeneca explores $400bn megadeal with US rival

Astrazeneca is exploring a $400bn merger with Bristol Myers Squibb, creating one of the world's largest pharma groups. The deal signals Astrazeneca's North America pivot and a broader pharma consolidation wave, reshaping cross-border governance.

Leggi questa versione → originale

benzinga.com1 g fa

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger - AstraZeneca (NYSE:AZN)

AstraZeneca negozia merger Bristol Myers Squibb ($400B), formando il 4° pharma maker mondiale con combined oncology leadership. BMS-Anthropic AI partnership accelera drug discovery; segnala consolidamento tech-enabled nel pharma e trend crescente AI adoption in healthcare R&D.

Leggi questa versione → originale

global.chinadaily.com.cn10 h fa

UK's AstraZeneca eyeing $400b merger, report says

AstraZeneca and BMS in merger talks for $400B pharma giant; AstraZeneca targets $80B revenue by 2030, investing $15B in China. Signals pharma consolidation trend; antitrust scrutiny on cancer division and UK relocation risk could block or reshape the deal.

Leggi questa versione → originale

independent.co.uk1 g fa

AstraZeneca ‘in talks to create £300bn pharmaceutical giant’

AstraZeneca and Bristol Myers Squibb in talks for £300 billion merger creating the fourth-largest pharma, facing Trump antitrust risks. The deal signals pharma M&A consolidation amid stricter compliance governance reshaping tech stack investments in life sciences.

Leggi questa versione → originale

domenica 2 agosto 2026·

straitstimes.com

Pharma giants AstraZeneca, Bristol Myers Squibb in talks on $512 billion megadeal: Report

The deal could create one of the world’s biggest pharmaceutical groups with a combined value of nearly US$400 billion. Read more at straitstimes.com. Read more at straitstimes.com.

domenica 2 agosto 2026·

benzinga.com

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger - AstraZeneca (NYSE:AZN)

AstraZeneca in talks to merge with Bristol Myers Squibb, creating $400B pharma giant, while talks ongoing for months, antitrust scrutiny is expected.

domenica 2 agosto 2026·

endpoints.news

AstraZeneca, Bristol Myers are in talks about merger — report

AstraZeneca & Bristol Myers Squibb in merger talks per Financial Times. AZ worth ~$265B, BMS ~$133B. Deal may involve stock & cash; talks may not lead to deal.

domenica 2 agosto 2026·

fortune.com

AstraZeneca said to have explored Bristol Myers merger | Fortune

Bristol Myers Squibb, which has a $133 billion market capitalization, could provide AstraZeneca with a bigger foothold in the US market.

lunedì 3 agosto 2026·

tgcom24.mediaset.it

Media, AstraZeneca tratta con Bristol Myers Squibb: maxi fusione da 400 miliardi

AstraZeneca tratta con Bristol Myers Squibb per una maxi fusione da 400 miliardi di dollari, nascerebbe il quarto colosso al mondo Big Pharma.

lunedì 3 agosto 2026·

ilsole24ore.com

Ft, AstraZeneca tratta con Bristol Myers Squibb maxi fusione da 400 miliardi

L’operazione darebbe vita al quarto colosso al mondo di Big Pharma per capitalizzazione di mercato

lunedì 3 agosto 2026·

tg24.sky.it

Ft: AstraZeneca tratta con Bristol Myers Squibb fusione da 400 mld

Leggi su Sky TG24 l'articolo Ft: AstraZeneca tratta con Bristol Myers Squibb maxi fusione da 400 miliardi di dollari

lunedì 3 agosto 2026·

handelsblatt.com

Pharma: Astra-Zeneca erwägt wohl Mega-Fusion mit Bristol-Myers Squibb

Es wäre eine der größten Fusionen in der Wirtschaftsgeschichte. Laut einem Medienbericht wurden entsprechende Gespräche geführt. Ob es zu einem Zusammenschluss kommt ist jedoch…

lunedì 3 agosto 2026·

manager-magazin.de

AstraZeneca: Pharmakonzern prüft 400-Milliarden-Dollar-Fusion mit Bristol Myers

AstraZeneca-Chef Pascal Soriot plant offenbar eine Fusion mit dem US-Pharmariesen Bristol Myers Squibb. Damit könnte ein Konzern im Wert von fast 400 Milliarden Dollar entstehen.…

lunedì 3 agosto 2026·

morningstar.com

AstraZeneca Held Talks to Combine With Bristol Myers Squibb, FT Says, Citing Sources

--AstraZeneca has held talks to combine with Bristol Myers Squibb, the Financial Times reports, citing unnamed sources.

lunedì 3 agosto 2026·

cityam.com

Astrazeneca explores $400bn megadeal with US rival

Astrazeneca is exploring a $400bn (£300bn) merger with US rival Bristol Myers Squibb to create one of the world's largest pharma groups

lunedì 3 agosto 2026·

independent.co.uk

AstraZeneca in talks over £300bn mega-merger with US rival – reports

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

lunedì 3 agosto 2026·

cnbc.com

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

AstraZeneca shares dropped as much as 7% after a report that the U.K.'s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that, if completed,…

lunedì 3 agosto 2026·

ansa.it

Financial Times: 'AstraZeneca tratta con Bristol Myers Squibb per una maxi fusione da 400 miliardi' - Notizie - Ansa.it

Il gruppo anglo-americano salirebbe al quarto posto per capitalizzazione tra Big Pharma (ANSA)

lunedì 3 agosto 2026·

newsbytesapp.com

AstraZeneca, BMS discuss $400B pharma mega-deal

AstraZeneca is reportedly exploring a $400 billion merger with U.S.-based Bristol Myers Squibb, potentially forming one of the largest pharmaceutical companies in history.

lunedì 3 agosto 2026·

milanofinanza.it

AstraZeneca e Bristol Myers trattano la maxi fusione, può nascere un colosso farmaceutico da 400 miliardi | MilanoFinanza News

L’operazione creerebbe il quarto gruppo farmaceutico mondiale per valore di Borsa e aprirebbe una nuova fase di consolidamento nel Big Pharma

lunedì 3 agosto 2026·

eldiario.es

Las farmacéuticas AstraZeneca y Bristol Myers Squibb negocian una fusión de 348.000 millones de euros

De prosperar las conversaciones, desveladas por Financial Times, la unión de la compañía británica y la estadounidense daría lugar a la cuarta empresa del mundo en este sector por…

lunedì 3 agosto 2026·

independent.co.uk

AstraZeneca ‘in talks to create £300bn pharmaceutical giant’

Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged…

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com